Lexicon Pharmaceuticals (NASDAQ: LXRX) presented Monday August 31, 2026 at ESC Congress 2026 Munich a post-hoc analysis of the Phase 3 SOLOIST-WHF trial of sotagliflozin (INPEFA, a dual SGLT1/SGLT2 inhibitor) evaluating efficacy and safety across the spectrum of baseline systolic blood pressure in patients recently hospitalized for worsening heart failure. The analysis was simultaneously published in JACC: Heart Failure (DOI 10.1016/j.jchf.2026.103368). Results: sotagliflozin's cardiovascular death and heart-failure-related event reduction was maintained regardless of baseline systolic blood pressure, including in patients with baseline SBP as low as 100 mmHg, without an increase in hypotension or acute kidney injury. The subgroup analysis strengthens the SGLT1/SGLT2 inhibitor commercial case in worsening heart failure where the class has historically been under-utilized due to concerns about hemodynamic tolerability in lower-blood-pressure patients.
Cytokinetics (NASDAQ: CYTK) confirmed Monday August 31, 2026 the peer-reviewed publication of ACACIA-HCM additional analyses in Circulation and MAPLE-HCM in Journal of the American College of Cardiology: Heart Failure, both following the ESC Congress 2026 Late-Breaking Clinical Trial Session presentations Saturday August 29 in Munich. The ACACIA-HCM Circulation paper details cardiac structure and diastolic function improvements from aficamten (Myqorzo) in symptomatic non-obstructive hypertrophic cardiomyopathy (LV mass reduction, LV wall thickness reduction, and LA volume reduction versus placebo at Week 36), supporting the ACACIA-HCM primary readout (KCCQ Clinical Summary Score and peak VO2) that was presented Friday August 28 in the Hot Line Session and published simultaneously in the New England Journal of Medicine. The MAPLE-HCM JACC: Heart Failure paper reports the trial of aficamten versus metoprolol in obstructive HCM. Cytokinetics plans an aficamten sNDA submission in Q4 2026 for the non-obstructive HCM indication.
Cytokinetics (NASDAQ: CYTK) presented Saturday August 29, 2026 additional results from the Phase 3 ACACIA-HCM (Myqorzo aficamten for non-obstructive HCM) and MAPLE-HCM trials in a Late-Breaking Clinical Trial Session at ESC Congress 2026 Munich, with simultaneous publications in Circulation and Journal of the American College of Cardiology: Heart Failure. The ACACIA-HCM additional analyses examined improvements in cardiac structure and diastolic function in patients with non-obstructive HCM (LV mass reduction, LV wall thickness reduction, and LA volume reduction versus placebo at Week 36), extending the primary readout (KCCQ Clinical Summary Score and peak VO2) presented in the Hot Line Session Friday August 28 and simultaneously published in NEJM. The follow-up data strengthens the aficamten commercial case for supplemental NDA in Q4 2026 and continues to differentiate the cardiac myosin inhibitor mechanism from mavacamten (Camzyos, Bristol Myers Squibb) which is currently approved only for obstructive HCM.